Profiling resistance patterns and signaling pathways in thoracic cancers
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
This study is trying to find out how certain factors in lung cancer patients can make treatments less effective and help develop better treatment options for those who are having surgery for non-small cell lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT05049837 on ClinicalTrials.gov |
What this trial studies
This project aims to utilize therapeutic target-focused profiling, genome-wide mRNA profiling, and assessments of tumor phosphopeptides and DNA in the bloodstream to understand how various molecular factors contribute to resistance to therapy, prognosis, and metastatic patterns in lung cancer. By examining factors that drive cell growth and promote resistance, the study seeks to identify new therapeutic targets and understand which targets may worsen patient outcomes. The research focuses on operable non-small cell lung carcinoma (NSCLC) patients undergoing surgical resection, with the goal of developing novel treatment approaches based on the findings.
Who should consider this trial
Good fit: Ideal candidates are patients with stage I-IIIA non-small cell lung cancer who are undergoing surgical resection with or without neoadjuvant chemotherapy.
Not a fit: Patients with advanced-stage lung cancer or those not undergoing surgical treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new therapeutic targets that improve treatment outcomes for lung cancer patients.
How similar studies have performed: Other studies have shown promise in identifying therapeutic targets in lung cancer, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Eligible patients should be ones who have stage I-IIIA non-small cell lung cancer (NSCLC) and undergo surgical resection with or without neoadjuvant chemotherapy as part of standard treatment, and have a information of demographics, smoking history, preoperative clinical data, and follow -up data including adjuvant therapy, relapse, and treatment at relapse. We will include the three major NSCLC histologic subtypes, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma - Exclusion Criteria: None
Where this trial is running
Houston, Texas
- M D Anderson Caner Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Luisa M Solis Soto, MD — M.D. Anderson Cancer Center
- Study coordinator: Luisa M Solis Soto, MD
- Email: lmsolis@mdanderson.org
- Phone: 832-794-1469
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.